Oct 24, 2024 / 12:00PM GMT
Christoffer Rosenblad - Xvivo Perfusion AB - CEO
And welcome to Xvivo's earning call for the third quarter of 2024.
On the first light today's presentation that are sitting in the same room, Christopher Rosengard co and besides me, Kristoffer Nordstrom CFO of X Perfusion.
And with that, we turn to slide 2 the Q3 financials at a glance and, and I'm proud and happy to report that Q3 shows improving our top line as well as EBITA compared to the same quarter last year, even though we have continued and we will continue to invest in the organization for for future growth. Sales came in at 191 million, which is the 41% organic growth and their data shows an improvement to 21%.
The growth for is main Forex is mainly coming from higher PS activity during the quarter. Another growth that we see in this quarter is the US R trial where we are seeing very high interest to join the trial as well as well as very high activity in the trial during the summer months.
And Kristoffer Nordstrom, our Chief Financial Officer will get into the details on sale, gross margin avatar and the
Q3 2024 Xvivo Perfusion AB Earnings Call Transcript
Oct 24, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers